Ultrasonographic Evaluation of Anovulatory Disorders in Lean and Overweight Women

Sponsor
Cornell University (Other)
Overall Status
Suspended
CT.gov ID
NCT03306849
Collaborator
Weill Medical College of Cornell University (Other)
150
1
88
1.7

Study Details

Study Description

Brief Summary

The investigators would like to determine whether ultrasound features of the ovaries can be used to reliably diagnose different types of anovulatory disorders in women across all body types. The study will also try to establish whether ultrasound features of the ovary can reflect the degree of reproductive and metabolic problems that a woman with irregular or absent periods might be experiencing.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This study is being conducted in order to determine if ultrasound features of the ovaries can be used to reliably diagnose different types of anovulatory disorders in women across all body types. The study will also try to establish whether ultrasound features of the ovary can reflect the degree of reproductive and metabolic problems that a woman with irregular or absent periods might be experiencing. In this way, the researchers can help to maximize the information that can be received when using ultrasound to evaluate patients with concerns over irregular menstrual cycles and/or infertility.

    The ovaries are the site of egg production and normally release one egg every month. The process of releasing an egg is called ovulation. The act of releasing an egg is the body's way of ensuring a woman's fertility each month during her reproductive years. There are a number of reasons why ovulation may not occur regularly in women. Some of these reasons are believed to relate to male hormone production (i.e. androgens), body composition, nutrition and overall metabolic health. However, the precise ways in which these factors affect ovulation are unknown.

    The researchers plan to evaluate how the ovaries look and function in a large group of women. Their goal is to recruit both lean and overweight women to this study and include both women that have regular, predictable menstrual cycles as well as those that have infrequent or absent menstrual cycles. The researchers will include women with irregular cycles due to increased androgen production, or hyperandrogenic anovulation - as well as those that have irregular cycles but normal androgen levels or normoandrogenic anovulation. The researchers will use ultrasound to collect information on how the ovaries look and function, and then relate the features of the ovaries to body composition, reproductive and metabolic hormones as well as nutritional factors. Because features of the ovaries are expected to be different in lean and overweight women, the researchers hope to develop ultrasound criteria that will help healthcare providers to diagnosis specific ovulation problems in women across all body sizes. Together, this research will help to better understand the complex relationship between nutrition, metabolism and reproductive health in women.

    To accomplish these objectives, the investigators plan to recruit 50 women with regular menstrual cycles, 50 women with normoandrogenic anovulation, and 50 women with hyperandrogenic anovulation. Their goal is to recruit an equal number of women in each group who are lean (BMI; Normal weight = 18.5 - 24.9 kg/m2) and overweight or obese (BMI; Overweight = 25 - 29.9 kg/m2; Obese >= 30kg/m2). Ultrasound scans of the ovaries will be assessed for the total number, size, and distribution of follicles using both two- and three-dimensional imaging techniques. Participants will have blood samples collected determine serum concentrations of luteinizing hormone (LH), follicle stimulating hormone (FSH), estradiol, progesterone. The following metabolic parameters will be assessed: (1) 75-gram oral glucose tolerance test to characterize glucose and insulin dynamics at 0, 30, 60, 90, and 120 minutes post-glucose ingestion; (2) dual X-ray absorptiometry (DXA) scan to quantify body fat and lean muscle distribution; (3) vitals and anthropometry assessment to measure waist and hip circumference, height, weight, blood pressure, and heart rate, and (4) fasting blood tests to detect serum concentrations of androgens (i.e., total testosterone, androstenedione, free androgen index) and serum markers of metabolic syndrome (i.e., lipids and hemoglobin A1C). Participants will complete a food frequency questionnaire and physical activity questionnaire. A researcher may also provide participants with an accelerometer to wear for a week.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    150 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Cross-Sectional
    Official Title:
    Ultrasonographic Evaluation of Anovulatory Disorders in Lean and Overweight Women
    Actual Study Start Date :
    Aug 1, 2015
    Anticipated Primary Completion Date :
    Dec 1, 2022
    Anticipated Study Completion Date :
    Dec 1, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    Regular menstrual cycles

    Women will be assigned to this category if they report a history of regular menstrual cycles (every 21 to 35 days). Recruitment will be targeted such that equal numbers of lean (BMI <25kg/m2) and overweight or obese (BMI >24.9kg/m2) participate.

    Normoandrogenic anovulation

    Women will be assigned to this category if they do not have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (<21 days or >35 days), including women with a pre-existing diagnosis of PCOS. Recruitment will be targeted such that equal numbers of lean (BMI <25kg/m2) and overweight or obese (BMI >24.9kg/m2) participate.

    Hyperandrogenic anovulation

    Women will be assigned to this category if they have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (<21 days or >35 days), including women with a pre-existing diagnosis of PCOS. Recruitment will be targeted such that equal numbers of lean (BMI <25kg/m2) and overweight or obese (BMI >24.9kg/m2) participate.

    Outcome Measures

    Primary Outcome Measures

    1. Follicle number per ovary [1 day]

      The number and size of all follicles in each ovary will be assessed by ultrasonography

    Secondary Outcome Measures

    1. Follicle number per cross section [1 day]

      The number all follicles in a single cross sectional plane of each ovary will be assessed by ultrasonography

    2. Ovarian volume [1 day]

      The size of each ovary will be determined by ultrasonography for each participant and compared across groups.

    3. Stromal echogenicity on ultrasound [1 day]

      The brightness of the ovarian stroma in a single cross section will be determined by ultrasonography for each participant and compared across groups.

    4. Ovarian area-stromal area ratio [1 day]

      The ratio of the stromal area to the total ovarian area of the ovary in a single cross section will be determined by ultrasonography for each participant and compared across groups.

    5. LH-FSH ratio [1 day]

      The ratio of circulating LH to FSH concentrations in the serum will be determined for each participant and compared across groups

    6. Hirsutism Score [1 day]

      Degree of hirsutism as judged by the Ferriman-Gallwey scale will be determined and compared across groups

    7. Androgen concentrations [1 day]

      Total testosterone, androstenedione and free androgen index concentrations in serum will be determined and compared across groups.

    8. Menstrual Cycle Length [1 day]

      Average menstrual cycle length as determined by self-reported history will be determined and compared across groups

    9. Serum markers of metabolic syndrome [1 day]

      Lipids, glucose and HbA1C concentrations will be determined and compared across groups.

    10. Blood Pressure [1 day]

      Blood pressure will be determined and compared across groups. [Time Frame: 1 day]

    11. Body mass index [1 day]

      The ratio of weight to height will be determined and compared across groups.

    12. Waist-to-hip ratio [1 day]

      The ratio of waist circumference to hip circumference will be determined and compared across groups

    13. Body fat distribution [1 day]

      Percentage and distribution of fat and lean mass as assessed using DXA technology will be compared across groups.

    14. Insulin sensitivity [1 day]

      Insulin sensitivity will be determined by administration of an oral glucose tolerance test and compared across groups.

    15. Differences in diet composition assessed via food frequency questionnaire [1 day]

      A food frequency questionnaire will be administered to assess diet composition for the last three months and will be compared across groups

    16. Differences in energy expenditure assessed via a waist-worn accelerometer [1 week]

      Participants will be asked to wear a small accelerometer device to assess physical activity

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Aged 18-45 years

    • At least 2y post-menarche

    • BMI >18.5kg/m2

    • Good visibility of the ovaries on ultrasound

    Either:
    • Regular menstrual cycles (21-35 days);

    • Irregular menstrual cycles (>35 days); or

    • Previous diagnosis of PCOS from a primary care provider

    Exclusion Criteria:
    • Weight >300lbs

    • Currently pregnant or breast feeding

    • History of ovarian surgery

    • Use of medications or supplements known or suspected to interfere with reproductive function and/or glucose and lipid metabolism in the past 3 months

    • Evidence of reproductive aging as assessed by the principal criteria of STRAW+10 stages

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Clinical and Translational Science Center New York New York United States 10065

    Sponsors and Collaborators

    • Cornell University
    • Weill Medical College of Cornell University

    Investigators

    • Principal Investigator: Marla E Lujan, PhD, Cornell University
    • Principal Investigator: Steven Spandorfer, MD, Weill Medical College of Cornell University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Cornell University
    ClinicalTrials.gov Identifier:
    NCT03306849
    Other Study ID Numbers:
    • 1410015577
    First Posted:
    Oct 11, 2017
    Last Update Posted:
    Dec 3, 2020
    Last Verified:
    Dec 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 3, 2020